|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4881175A
(en)
|
1986-09-02 |
1989-11-14 |
Genex Corporation |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US5013653A
(en)
|
1987-03-20 |
1991-05-07 |
Creative Biomolecules, Inc. |
Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
ATE243754T1
(de)
|
1987-05-21 |
2003-07-15 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US6267964B1
(en)
|
1989-08-01 |
2001-07-31 |
Affibody Technology Sweden Ab |
Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
|
|
SE509359C2
(sv)
|
1989-08-01 |
1999-01-18 |
Cemu Bioteknik Ab |
Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
EP0571613B1
(en)
|
1991-12-13 |
2003-09-17 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
|
EP1240337B1
(en)
|
1999-12-24 |
2006-08-23 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
|
AU2002335930B2
(en)
|
2001-03-09 |
2005-07-28 |
Morphosys Ag |
Serum albumin binding moieties
|
|
EP1576172A2
(en)
|
2002-06-21 |
2005-09-21 |
Dyax Corporation |
Serum protein-associated target-specific ligands and identification method therefor
|
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
AU2003244817B2
(en)
|
2002-06-28 |
2010-08-26 |
Domantis Limited |
Antigen-binding immunoglobulin single variable domains and dual-specific constructs
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
CA2502413A1
(en)
|
2002-11-01 |
2004-05-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
|
|
TW200607523A
(en)
|
2004-06-01 |
2006-03-01 |
Domantis Ltd |
Drug compositions, fusions and conjugates
|
|
AU2005311098B2
(en)
|
2004-12-01 |
2011-08-11 |
Allergan, Inc. |
Non-cytotoxic protein conjugates
|
|
EP2535349A1
(en)
|
2007-09-26 |
2012-12-19 |
UCB Pharma S.A. |
Dual specificity antibody fusions
|
|
CA2737241C
(en)
|
2008-09-26 |
2017-08-29 |
Ucb Pharma S.A. |
Multivalent antibody fusion proteins
|
|
WO2011006915A2
(en)
|
2009-07-16 |
2011-01-20 |
Glaxo Group Limited |
Improved anti-serum albumin binding single variable domains
|
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
ES2702315T3
(es)
|
2012-08-24 |
2019-02-28 |
Univ California |
Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
CA2963696A1
(en)
*
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
|
|
EP3204415B1
(en)
|
2014-10-09 |
2020-06-17 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and ror1
|
|
IL293435B1
(en)
*
|
2015-06-15 |
2026-04-01 |
Numab Therapeutics AG |
Heterodimeric multispecific antibody format
|
|
TW201734049A
(zh)
|
2016-01-22 |
2017-10-01 |
健生生物科技公司 |
抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法
|
|
WO2017142928A1
(en)
|
2016-02-17 |
2017-08-24 |
Macrogenics, Inc. |
Ror1-binding molecules, and methods of use thereof
|
|
WO2018014001A1
(en)
*
|
2016-07-14 |
2018-01-18 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
|
WO2018224441A1
(en)
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
SG11201911527QA
(en)
*
|
2017-06-05 |
2020-01-30 |
Numab Therapeutics AG |
Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
|
|
GB201710838D0
(en)
*
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
|
EP3459968A1
(en)
|
2017-09-20 |
2019-03-27 |
Numab Innovation AG |
Novel stable antibody variable domain framework combinations
|
|
TWI899079B
(zh)
|
2019-05-23 |
2025-10-01 |
美商維洛斯生物公司 |
抗ror1/抗cd3雙特異性結合分子
|